Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for AEON Biopharma, Inc. (AEON : AMEX)

• Company Description    AEON Biopharma Inc. is a clinical-stage biopharmaceutical company. It focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions. AEON Biopharma Inc., formerly known as Priveterra Acquisition Corp., is based in IRVINE, Calif. Number of Employees: 8

• Price / Volume Information    Yesterday's Closing Price: $0.24 Daily Weekly Monthly 20 Day Moving Average: 7,099,787 shares Shares Outstanding: 49.88 (millions) Market Capitalization: $11.97 (millions) Beta: 0.69 52 Week High: $1.45 52 Week Low: $0.18 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -7.80% -6.83% 12 Week -6.00% -8.29% Year To Date -78.19% -81.02%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 130 VANTIS DR. SUITE 170 - ALISO VIEJO,CA 92656 USA ph: 949-354-6499 fax: - investor.relations@aeonbiopharma.com http://www.aeonbiopharma.com

• General Corporate Information    Officers Robert Bancroft - Chief Executive Officer and President Jost Fischer - Chairman Shelley Thunen - Director Robert Palmisano - Director Eric Carter - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 00791X209 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/13/26 Share - Related Items Shares Outstanding: 49.88 Most Recent Split Date: 2.00 (0.01:1) Beta: 0.69 Market Capitalization: $11.97 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.09 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.55 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/13/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 96.67% vs. Previous Quarter: 95.45% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 09/30/26 - - 06/30/26 - - 03/31/26 - - ROA 09/30/26 - - 06/30/26 - -839.47 03/31/26 - -763.32 Current Ratio 09/30/26 - - 06/30/26 - 0.54 03/31/26 - 0.99 Quick Ratio 09/30/26 - - 06/30/26 - 0.54 03/31/26 - 0.99 Operating Margin 09/30/26 - - 06/30/26 - - 03/31/26 - - Net Margin 09/30/26 - - 06/30/26 - - 03/31/26 - - Pre-Tax Margin 09/30/26 - - 06/30/26 - - 03/31/26 - - Book Value 09/30/26 - - 06/30/26 - -0.58 03/31/26 - -0.66 Inventory Turnover 09/30/26 - - 06/30/26 - - 03/31/26 - - Debt-to-Equity 09/30/26 - - 06/30/26 - - 03/31/26 - - Debt-to-Capital 09/30/26 - - 06/30/26 - - 03/31/26 - -

Powered by Zacks Investment Research ©